NAFDAC don approve R21 malaria vaccine
Di National Agency for Food and Drug Administration and Control, NAFDAC, on Monday, yarn say dem don approve di use of di R21 malaria vaccine produced by di Serum Institute of India.
Prof Mojisola Adeyeye, Director General of di agency, make di announcement during press briefing for Abuja.
Di development dey come a few days after Ghana approve di malaria vaccine wey dey developed for di University of Oxford.
FOR MORE NEWS: Dino Melaye don win Kogi PDP governorship primary
According to di NAFDAC Director, di vaccine na for di prevention of clinical malaria in children within the age of 5 months to 36 months.
She reveal say di country expects to get at least 100,000 doses of di new vaccine in donations before the market authorisation makes other arrangements, particularly with di National Primary Health Care Development Agency.
“NAFDAC in exercising its mandate as stipulated by its enabling law, NAFDAC Act CapN1, LFN 2004 is granting registration approval for R21 Malaria Vaccine (Recombinant, Adjuvanted) manufactured by Serum Institute of India Pvt. Ltd.” Na wetin Adeyeye tok be dat.
You fit go read di tori as NAFDAC approve R21 malaria vaccine…READ MORE
